Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/205327
Title: | Accuracy and Survival Outcomes after National Implementation of Sentinel Lymph Node Biopsy in Early Stage Endometrial Cancer |
Author: | Cabrera, Silvia Gómez Hidalgo, Natalia R. García Pineda, Virginia Bebia, Vicente Fernández González, Sergi Alonso, Paula Rodríguez Gómez, Tomás Fusté, Pere Gracia Segovia, Myriam Lorenzo, Cristina Chacon, Enrique Roldan Rivas, Fernando Arencibia, Octavio Martí Edo, Marina Fidalgo, Soledad Sanchis, Josep Padilla Iserte, Pablo Pantoja Garrido, Manuel Martínez, Sergio Peiró, Ricard Escayola, Cecilia Oliver Pérez, M. Reyes Aghababyan, Cristina Tauste, Carmen Morales, Sara Torrent, Anna Utrilla Layna, Jesus Fargas, Francesc Calvo, Ana Aller de Pace, Laura Gil Moreno, Antonio Spain-GOG And The Multisent Study Group |
Issue Date: | 26-Aug-2023 |
Publisher: | Springer Science and Business Media LLC |
Abstract: | Background. Sentinel lymph node (SLN) biopsy has recently been accepted to evaluate nodal status in endometrial cancer at early stage, which is key to tailoring adjuvant treatments. Our aim was to evaluate the national implementation of SLN biopsy in terms of accuracy to detect nodal disease in a clinical setting and oncologic outcomes according to the volume of nodal disease. Patients and Methods. A total of 29 Spanish centers participated in this retrospective, multicenter registry including patients with endometrial adenocarcinoma at preoperative early stage who had undergone SLN biopsy between 2015 and 2021. Each center collected data regarding demographic, clinical, histologic, therapeutic, and survival characteristics. Results. A total of 892 patients were enrolled. After the surgery, 12.9% were suprastaged to FIGO 2009 stages III-IV and 108 patients (12.1%) had nodal involvement: 54.6% macrometastasis, 22.2% micrometastases, and 23.1% isolated tumor cells (ITC). Sensitivity of SLN biopsy was 93.7% and false negative rate was 6.2%. After a median follow up of 1.81 years, overall surivial and disease-free survival were significantly lower in patients who had macrometastases when compared with patients with negative nodes, micrometastases or ITC. Conclusions. In our nationwide cohort we obtained high sensitivity of SLN biopsy to detect nodal disease. The oncologic outcomes of patients with negative nodes and low-volume disease were similar after tailoring adjuvant treatments. In total, 22% of patients with macrometastasis and 50% of patients with micrometastasis were at low risk of nodal metastasis according to their preoperative risk factors, revealing the importance of SLN biopsy in the surgical management of patients with early stage EC. |
Note: | Reproducció del document publicat a: https://doi.org/10.1245/s10434-023-14065-3 |
It is part of: | Annals of Surgical Oncology, 2023, vol. 30, num. 12, p. 7653-7662 |
URI: | http://hdl.handle.net/2445/205327 |
Related resource: | https://doi.org/10.1245/s10434-023-14065-3 |
ISSN: | 1534-4681 |
Appears in Collections: | Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
s10434-023-14065-3.pdf | 545.57 kB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License